Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL256780 | 1.00 | AVPR2 (0.70) | AVPR2AVPR1A | |
| SCHEMBL257238 | 1.00 | AVPR2 (0.70) | AVPR2AVPR1A | |
| SCHEMBL13158519 | 0.91 | AVPR2 (0.60) | AVPR2AVPR1A | |
| SCHEMBL22365957 | 0.91 | AVPR2 (0.71) | AVPR2AVPR1A | |
| SCHEMBL19564901 | 0.91 | AVPR2 (0.71) | AVPR2AVPR1A | |
| SCHEMBL19564902 | 0.91 | AVPR2 (0.71) | AVPR2AVPR1A | |
| SCHEMBL23130460 | 0.88 | AVPR2 (0.57) | AVPR2AVPR1A | |
| SCHEMBL19540592 | 0.88 | AVPR2 (0.64) | AVPR2AVPR1A | |
| SCHEMBL21026200 | 0.88 | AVPR2 (0.64) | AVPR2AVPR1A | |
| SCHEMBL257237 | 0.88 | AVPR2 (0.70) | AVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11331314-B2 | Amine substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-05-17 | — | — | US | disclosed |
| US-11298367-B2 | Prodrugs of substituted triazole derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-12 | — | — | US | disclosed |
| US-11230540-B2 | Substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-01-25 | — | — | US | disclosed |
| US-11173151-B2 | Substituted triazole derivatives and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-11-16 | — | — | US | disclosed |
| EP-3700913-B1 | PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | BAYER AG (DE) | 2021-11-10 | — | — | EP | disclosed |
| US-11149023-B2 | Substituted triazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-19 | — | — | US | disclosed |
| US-20210253557-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-19 | — | — | US | disclosed |
| US-11091463-B2 | Amide-substituted pyridinyltriazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-17 | — | — | US | disclosed |
| US-11091463-B2 | Amide-substituted pyridinyltriazole derivatives and uses thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-08-17 | — | — | US | disclosed |
| CN-113121504-A | Amide-substituted pyridyl triazole derivatives and use thereof | 拜耳制药股份公司 | 2021-07-16 | — | — | CN | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| WO-2010105770-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2007134862-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER HEALTHCARE AG (DE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11331314-B2 | Amine substituted triazole derivatives and uses thereof | GLS, TNNI3, NAT1 | AVPR2 1052/4885AVPR1A 1988/4885 |
| US-11230540-B2 | Substituted triazole derivatives and uses thereof | GLS, TNNI3, CYP11B2 | AVPR2 1574/4885AVPR1A 2827/4885 |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | AVPR2 1/4885AVPR1A 2/4885 |
| US-20210253557-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF | GLS, TNNI3, CYP11B2 | AVPR2 1574/4885AVPR1A 2827/4885 |
| US-20100261771-A1 | SUBSTITUTED 2-ACETAMIDO-5-ARYL-1,2,4-TRIAZOLONES AND USE THEREOF | AADAC, NAT1, TNNT2 | AVPR2 2370/4885AVPR1A 3230/4885 |
| US-11149023-B2 | Substituted triazole derivatives and uses thereof | GLS, TNNI3, CYP11B2 | AVPR2 1574/4885AVPR1A 2827/4885 |
| US-11173151-B2 | Substituted triazole derivatives and uses thereof | GLS, TNNI3, CYP11B2 | AVPR2 1574/4885AVPR1A 2827/4885 |
| US-11091463-B2 | Amide-substituted pyridinyltriazole derivatives and uses thereof | AADAC, GLS, PDXK | AVPR2 1068/4885AVPR1A 2095/4885 |
| US-11298367-B2 | Prodrugs of substituted triazole derivatives and uses thereof | CYP4B1, AADAC, GLS | AVPR2 2259/4885AVPR1A 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.